ARS Pharmaceuticals, Inc.
SPRY
$15.80
-$0.11-0.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -229.77% | 796.62% | -28.67% | 27.94% | 31.21% |
| Total Depreciation and Amortization | 2,445.45% | 141.67% | 0.00% | -10.00% | -45.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.96% | 393.47% | 68.26% | 322.25% | 202.72% |
| Change in Net Operating Assets | -565.97% | 1.13% | 178.32% | 1,021.79% | 7.97% |
| Cash from Operations | -507.18% | 341.33% | -13.35% | 56.33% | 46.01% |
| Capital Expenditure | -9.64% | -431.87% | -225.58% | -26.67% | 56.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 445.85% | -491.01% | 136.39% | -128.02% | 92.43% |
| Cash from Investing | 441.41% | -490.80% | 136.06% | -128.12% | 92.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 181.01% | -15.07% | -26.17% | -80.90% | -80.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 181.01% | 3,828.86% | -26.17% | -80.90% | -80.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.81% | 6.91% | 105.18% | -162.21% | 87.80% |